Paraoxonase/arylesterase in serum of patients with type II diabetes mellitus

Acta Pharmaceutica

Volumn 56, Issue 1, 2006, Pages 59-68

  Juretić, Dubravka ^a   Motejlkova, Alena ^b   Kunović, Branka ^c   Rekić, Branka ^c   Flegar Meštrić, Zlata ^d   Vujić, Lovorka ^a   Mesić, Ranko ^d   Lukač Bajalo, Jana ^e   Simeon Rudolf, Vera ^f  

^a UNIVERSITY OF ZAGREB   (Croatia)

^b Charles University in Prague Faculty of Pharmacy   (Czech Republic)

^c Zagreb Centar Health Center   (Croatia)

^d University of Zagreb   (Croatia)

^e UNIVERSITY OF LJUBLJANA   (Slovenia)

^f INSTITUTE FOR MEDICAL RESEARCH AND OCCUPATIONAL HEALTH   (Croatia)

Author keywords

Arylesterase; Lipid status; Paraoxonase; Type II diabetes mellitus

Indexed keywords

ARYLDIALKYLPHOSPHATASE; ARYLESTERASE; INSULIN; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; ORAL ANTIDIABETIC AGENT; PARAOXON; PHENYLACETIC ACID; TRIACYLGLYCEROL;

ADULT; AGED; ALLELE; ARTICLE; ATHEROSCLEROSIS; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; COMPARATIVE STUDY; CONTROLLED STUDY; DIET THERAPY; ENZYME ACTIVITY; ENZYME ANALYSIS; ENZYME BLOOD LEVEL; ENZYME LOCALIZATION; FEMALE; HUMAN; LIPID OXIDATION; MAJOR CLINICAL STUDY; MALE; MOLECULAR WEIGHT; NON INSULIN DEPENDENT DIABETES MELLITUS; ORAL GLUCOSE TOLERANCE TEST; PHENOTYPE; RISK ASSESSMENT; SPECTROPHOTOMETRY; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 32844457690     PISSN: 13300075     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. E. Reiner, Z. Radić and V. Simeon, Hydrolysis of Paraoxon and Phenylacetate by Human Serum Esterases, in Enzymes Hydrolyzing Organophosphorus Compounds (Eds. E. Reiner, W. N. Aldridge and F. C. G. Hoskin), Elis Horwood, Chichester 1987, pp. 30-40.
2. B. N. La Du, M. Aviram, S. Billecke, N. Navab, S. Primo-Parma, R. C. Sorensen and T. J. Standford, On the physiological role(s) of the paraoxonases, Chem. Biol. Interact. 119-120 (1999) 379-388.
3. J. F. Teiber, D. I. Draganov and B. N. La Du, Lactonase and lactonizing activities of human paraoxonase (PON1) and rabbit serum PON3, Biochem. Pharmacol. 66 (2003) 887-896.
4. D. I. Draganov and B. N. La Du, Pharmacogenetics of paraoxonase: a brief review, Naunyn-Schmiedeberg's Arch. Pharmacol. 369 (2004) 78-88.
5. S. Adkins, K. N. Gan, M. Mody and B. N. La Du, Molecular basis for the polymorphic forms of human serum paraoxonase/arylesterase: Gln or Arg at position 192, for the respective A or B allozymes, Am. J. Hum. Genet. 40 (1991) 277-282.
6. M. I. Mackness and P. N. Durrington, HDL, its enzymes and its potential to influence lipid peroxidation, Atherosclerosis 115 (1995) 243-253.
7. A. D. Watson, J. A. Berliner, S. Y. Hama, B. N. La Du, K. F. Faull, A. M. Fogel and M. Navab, Protective effect of high density lipoprotein associated paraoxonase. Inhibition of the biological activity of minimally oxidized low density lipoprotein, J. Clin. Invest. 96 (1995) 2882-2891.
8. P. M. Laplaud, T. Dantoine and M. J. Chapman, Paraoxonase as a risk marker for cardiovascular disease: facts and hypotheses, Clin. Chem. Lab. Med. 37 (1998) 431-441.
9. C. J. Ng, D. M. Shib, S. Y. Hama, N. Villa, M. Navab and S. T. Reddy, The paraoxonase gene family and atherosclerosis, J. Free Radical Biol. Med. 38 (2005) 153-163.
10. S. P. Deakin and R. W. James, Genetic and environmental factors modulating serum concentrations and activities of the antioxidant enzyme paraoxonase-I, Clin. Sci. 107 (2004) 435-447.
11. B. Mackness, P. N. Durrington and M. I. Mackness, Paraoxonase 1 activity, concentration and genotype in cardiovascular disease, Curr. Opin. Lipidol. 15 (2004) 399-404.
12. J. W. Baynes and S. R. Thorpe, Role of oxidative stress in diabetic complications: a new perspective on an old paradigm, Diabetes 48 (1999) 1-9.
13. M. Boemi, I. Leview, C. Sirolla, C. Pieri, M. Marra and R. W. James, Serum paraoxonase is reduced in type 1 diabetic patients compared to non-diabetics, first degree relatives; influence on the ability of HDL to protect LDL from oxidation, Atherosclerosis 155 (2001) 229-235.
14. B. Mackness, P. N. Durrington, A. J. Boulton, D. Hine and M. I. Mackness, Serum paraoxonase activity in patients with type 1 diabetes compared to healthy controls, Eur. J. Clin. Invest. 32 (2002) 256-259.
15. Y. Hu, H. Tian and R. Liu, Gln/Arg 192 polymorphism of paraoxonase 1 is associated with carotid intima-media thickness in patients of type 2 diabetes mellitus of Chinese, Diabetes Res. Clin. Pract. 61 (2003) 21-27.
16. M. Koch, S. Hering, C. Barth, M. Ehren, M. D. Enderle and M. Pfohl, Paraoxonase 1 192 Gln/Arg gene polymorphism and cerebrovascular disease interaction with type 2 diabetes, Exp. Clin. Endocrinol. Diabetes 109 (2001) 141-145.
17. D. Osei-Hyiaman, L. Hou, F. Mengbai, R. Zhiyin, Z. Zhiming and K. Kano, Coronary artery disease risk in Chinese type 2 diabetics: is there a role for paraoxonase 1 gene (Q192R) polymorphism? Eur. J. Endocrinol. 144 (2001) 639-644.
18. M. Aviram, E. Hardak, J. Vaya, S. Mahmood, S. Milo, A. Hoffman, S. Billecke and D. Draganov, Human serum paraoxonase (PON1) Q and R selectively decrease lipid peroxides in human coronary and carotid atherosclerotic lesions: PON1 esterase and peroxidase like activity, Circulation 101 (2000) 2510-2517.
19. H. Cao, A. Girard-Globa, F. Berthezene and P Moulin, Paraoxonase protection of LDL against peroxidation is independent of its esterase activity towards paraoxon and is unaffected by the Q→R genetic polymorphism, J. Lip. Res. 40 (1999) 133-139.
20. G. P. Jarvik, L. S. Rozek, V. H. Brophy, T. S. Hatsukami, R. J. Richter, G. D. Schellenberg and C. E. Furlong, Paraoxonase (PON1) phenotype is a better predictor of vascular disease than is PON1(192) or PON1(55) genotype, Arterioscl. Throm. Vas. Biol. 20 (2000) 2441-2447.
21. M. I. Mackness, D. Harty, D. Bhatnagar, P. H. Wincour, S. Arrol, M. Ishola and P. N. Durrington, Serum paraoxonase activity in familial hypercholesterolaemia and insulin-dependent diabetes mellitus, Atherosclerosis 86 (1991) 193-199.
22. D. Juretić, M. Tadijanović, B. Rekić, V. Simeon-Rudolf, E. Reiner and M. Baričić, Serum paraoxonase activity in hemodialyzed uremic patients: cohort study, Croat. Med. J. 42 (2001) 146-150.
23. H. W. Eckerson, C. M. Wyte and B. N. La Du, The human serum paraoxonase/arylesterase polymorphism, Am. J. Hum. Genet. 35 (1983) 1126-1138.
24. W. T. Friedewald, R. I. Levy and D. S. Fredrickson, Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge, Clin. Chem. 18 (1972) 499-502.
25. E. Reiner, V. Simeon-Rudolf and M. Škrinjarić- Špoljar, Catalytic properties and distribution profiles of paraoxonase and cholinesterase phenotypes in human sera, Toxicol. Lett. 82/83 (1995) 447-452.
26. J. Ruiz, A. Morabia, H. Blanche, R. W. James, M-C. B. Garin, G. Charpentier, Ph. Passa, C. Vaisse, J. Ruiz and Ph. Froguel, The Gln-Arg 192 polymorphism of paraoxonase and coronary disease in type 2 diabetes, Lancet 346 (1995) 869-872.
27. D. N. Nevin, A. Zambon, C. E. Furlong, R. J. Richter, R. Humbert, J. E. Hokanson and J. D. Brunzell, Paraoxonase genotypes, lipoprotein lipase activity and HDL, Arterioscler. Thromb. Vasc. Biol. 160 (1996) 1243-1249.